Entrada Therapeutics Inc TRDA

-- Announced following World Duchenne Awareness Day on September 7, grants are designed to support projects bridging healthcare disparities across the global Duchenne community -- BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the recipients of its 2026 DREAMS Grant Program: a competitive annual program that awards two $50,000 grants in support of projects working to better identify, understand and reach members of the Duchenne muscular dystr

BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 61,365 restricted stock units (“RSUs”) and options to purchase 19,425 shares of the Company’s common stock to eight newly-hired non-executive employees under the Company’s 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of September 1, 2026. The options have an exercise price of $7.07 per share, which is equal to the closing price of the

-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- -- Company to report ELEVATE-45-201 Cohort 1 data in October 2026 -- -- ELEVATE-45-201 Cohort 2 dosing ongoing at the increased dose of 10 mg/kg with data expected in H1 2027 -- -- Vertex to report VX-670 Phase 1/2 data in people living with DM1 in H2 2026 -- BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -9.68% and -73.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

-- Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201 -- -- Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026 -- BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight participants enrolled in Cohort 1 of the double-blind, placebo-controlled, multiple ascendin

At a 6 mg/kg dose, ENTR-601-44 didn’t elevate dystrophin levels to analyst expectations, or to the baseline change recorded by Novartis’ del-zota.

Sarepta stock toppled Thursday as investors digested the better-than-feared sales of its beleaguered gene therapy, Elevidys.

Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index decreasing 0.6%

While the company claimed a victory, analysts said data from a Phase 1/2 study fell short of expectations. Entrada shares subsequently tumbled more than 50%.

-- Announced positive ELEVATE-44-201 Cohort 1 topline results in Duchenne muscular dystrophy showing favorable safety, tolerability and early functional benefit -- -- Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026, as well as ELEVATE-44-201 open-label period and Cohort 2 data by year-end 2026 -- -- Cash runway expected into Q3 2027 with $255 million in cash, cash equivalents and marketable securities as of March 31, 2026 -- -- Entrada to host investor webcast and conference

-- Achieved the primary objective with favorable safety and tolerability, no discontinuations and no serious adverse events -- -- Markers of kidney function via eGFR, Cystatin C and magnesium were all within normal ranges and comparable to placebo -- -- Observed lower plasma exposure in Cohort 1 participants who are all between six and 17 years of age when compared with healthy adult volunteers; A similar trend was seen between recently received juvenile and adult NHP PK data -- -- Consequently,

BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) will announce topline results from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion of the Phase 1/2 ELEVATE-44-201 clinical study of ENTR-601-44 on Thursday, May 7, 2026. The Company will host an investor webcast and conference call at 8:30 a.m. ET to discuss these clinical results. The webcast can be accessed by visiting the Investor Relations section of the Company’s website at

Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.

This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies.